Anxiety disorders are a group of disorders that share symptoms like excessive fear and heightened stress (American Psychological Association [APA], 2022). It is important to note that fear and anxiety ...
- Voyage is the first-ever Phase 3 study of lysergide D-tartrate (LSD) with the primary endpoint measuring the change from baseline in the Hamilton Anxiety Rating Scale (HAM-A) score at week 12 for ...
PITTSBURGH, March 23, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has approved Effexor ® ...
Definium Therapeutics, Inc. (“Definium” or the “Company”), announced results from a retrospective, longitudinal study published in the Journal of Mood and Anxiety Disorders examining the real-world ...
NEW YORK--(BUSINESS WIRE)--Researchers from Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product ...
Mind Medicine (MindMed) has dosed the first subject in the Phase III Panorama study of a proprietary form of lysergide ...
Mind Medicine (MindMed) MNMD is developing its lead pipeline candidate, MM120, an orally disintegrating tablet (ODT) and a pharmaceutically optimized form of lysergide D-tartrate (LSD), for the ...
Findings highlight the link between anxiety severity and SI, underscoring the need for routine screening NEW YORK--(BUSINESS WIRE)-- Researchers from Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results